Cargando…

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study

OBJECTIVES: Our objective was to investigate the effectiveness and safety of silodosin in patients with benign prostatic hyperplasia (BPH) who switched to silodosin from another α(1) blocker because of inadequate response. METHODS: This was a prospective observational study conducted at 715 medical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Hiroshi, Kubono, Shinichi, Taneyama, Takehiko, Kuramoto, Kiyotoshi, Mizutani, Hideki, Tanaka, Noriko, Yoshida, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380964/ https://www.ncbi.nlm.nih.gov/pubmed/30607819 http://dx.doi.org/10.1007/s40268-018-0258-4

Ejemplares similares

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
por: Kim, Young Won, et al.
Publicado: (2015)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
por: Hagovska, Magdalena, et al.
Publicado: (2021)

Efficacy and Safety of the Selective α(1A)-Adrenoceptor Blocker Silodosin for Severe Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Prospective, Single-Open-Label, Multicenter Study in Korea
por: Moon, Ki Hak, et al.
Publicado: (2014)

Benign prostatic hyperplasia: An overview of existing treatment
por: Dhingra, Neelima, et al.
Publicado: (2011)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies
por: Gittelman, Marc C, et al.
Publicado: (2010)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy
por: Karaca, Umut, et al.
Publicado: (2021)

Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study
por: Patil, Siddangouda B., et al.
Publicado: (2017)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
por: Shimizu, Shogo, et al.
Publicado: (2015)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

The Hippocratic Splash
por: Girithari, Geetha, et al.
Publicado: (2018)

Performance of materials used for biological personal protective equipment against blood splash penetration
por: SHIMASAKI, Noriko, et al.
Publicado: (2017)

Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Transportation: Hybrid Splash
por: Black, Harvey
Publicado: (2008)

A Suspected Case of Silodosin-Induced Erythroderma
por: Liu, Annie, et al.
Publicado: (2015)

Silodosin-associated intraoperative floppy iris syndrome
por: Chatterjee, Samrat, et al.
Publicado: (2017)

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?
por: Eleazu, Chinedum, et al.
Publicado: (2017)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial
por: Rahman, Md Jawaid, et al.
Publicado: (2017)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
por: Nishimura, Akihiko, et al.
Publicado: (2021)

First beam splashes at the LHC
por: CERN Bulletin
Publicado: (2015)

ATLAS "Splash event" 2008
por: ATLAS, Experiment
Publicado: (2014)

Splashed by a clear liquid
por: Yang, Kai-Wei, et al.
Publicado: (2017)

Suppression of benign prostate hyperplasia by Kaempferia parviflora rhizome
por: Murata, Kazuya, et al.
Publicado: (2013)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Benign Prostatic Hyperplasia
Publicado: (2015)

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e8f4klcubth8tq1nl9blt5sgg0